Clinical Trial Update: Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin [Phase 1, Phase 2]

View source ↗

Summary

An update on Pharmasset's adaptive Phase I/II hepatitis C trial of a nucleoside analogue in combination with interferon and ribavirin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Interferon Alfa (interferon alfa)
• Ribavirin (ribavirin)
• Sofosbuvir (sofosbuvir)

Snippet

Sponsor: Pharmasset | Conditions: Healthy Volunteers, Hepatitis C Virus | Phase 1, Phase 2 | Status: COMPLETED